ONCY News and Press, Oncolytics Biotech Inc. From 09/07/22

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors PR Newswire Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO ...

Oncolytics Biotech Inc. (ONCY) Q2 2022 Results Conference Call August 11, 2022 08:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Matthew Coffey - President and Chief Executive Officer Kirk Look - Chief Financial Offic...

Oncolytics Biotech press release ( NASDAQ: ONCY ): Q2 GAAP EPS of -$0.09 misses by $0.01 . $33.7M in cash and cash equivalents provides projected runway into the second half of 2023 and through key clinical readouts in breast and pancreatic cancer. For further de...

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights Canada NewsWire Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational st...

Oncolytics Biotech ( NASDAQ: ONCY ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.08 (+38.5% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 ...

Major earnings expected before the bell on Thursday include: Arrival ( ARVL ) Brookfield Asset Management ( BAM ) Cardinal Health ( CAH ) Hanesbrands ( HBI ) Himax Technologies ( HIMX ) For further details see: Notable earnings before Thur...

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights Canada NewsWire Conference call and webcast to take place on Thursday, August 11, 2022 , at 8:30 a.m. ET SAN DIEGO, CA and...

Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors such as the increasing prevalence and inc...

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET Canada NewsWire Partial responses achieved in all patients in cohort's 1b portion Expansion criteria for pancreatic cancer cohort has been met to allow...

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors PR Newswire Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired...